Sweden's AddLife Q4 sales miss estimates

AddLife AB

04/02/2026 06:54

Overview

Sweden's life science firm Q4 sales fell 3%, missing analyst expectations

Profit after tax for Q4 rose 177% yr/yr

Company completed two acquisitions, expected to add SEK 50 mln in annual sales

Outlook

AddLife enters 2026 with improved profitability and a strong balance sheet

Company initiates increased acquisition activity for future growth

Result Drivers

MARGIN IMPROVEMENT - EBITA margin improved to 12.4% from 12.3%, indicating positive margin development

STRONG CASH FLOW - Cash flow from operating activities increased to SEK 888 mln, aiding debt reduction

ACQUISITIONS - Two acquisitions completed, expected to add SEK 50 mln in annual sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Miss
SEK 2.73 bln
SEK 2.80 bln (4 Analysts)
Q4 EPS
SEK 2.13
Q4 Net Income
SEK 260 mln
Q4 Adjusted Free Cash Flow
SEK 888 mln
Q4 EBITA
SEK 497 mln
Q4 EBITA Margin
12.40%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AddLife AB is SEK214.00, about 58.5% above its February 3 closing price of SEK135.00

The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 41 three months ago

Press Release: ID:nMFNcgMNFH

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)